AstraZeneca (LON:AZN) Hits New 52-Week Low – Time to Sell?

Shares of AstraZeneca PLC (LON:AZN) reached a new 52-week low on Wednesday . The company traded as low as GBX 9,641 ($125.14) and last traded at GBX 9,656 ($125.34), with a volume of 99590781 shares changing hands. The stock had previously closed at £103.74 ($134.66).

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on AZN shares. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research note on Friday, March 7th. Berenberg Bank restated a “buy” rating and set a GBX 140 ($1.82) target price on shares of AstraZeneca in a research report on Wednesday, March 26th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a report on Wednesday, February 19th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 6,303.50 ($81.82).

AstraZeneca Price Performance

The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83. The stock has a market cap of £192.23 billion, a P/E ratio of 27.39, a P/E/G ratio of 0.86 and a beta of 0.17. The firm has a 50 day moving average price of £114.66 and a 200 day moving average price of £111.31.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.